These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 21386792

  • 21. Adrenal cortical carcinoma.
    Dackiw AP, Lee JE, Gagel RF, Evans DB.
    World J Surg; 2001 Jul; 25(7):914-26. PubMed ID: 11572033
    [Abstract] [Full Text] [Related]

  • 22. [Adrenocortical carcinoma and its treatment].
    Tupikowski W, Bednarek-Tupikowska G, Florczak A.
    Postepy Hig Med Dosw (Online); 2004 Feb 26; 58():27-36. PubMed ID: 15069374
    [Abstract] [Full Text] [Related]

  • 23. [Recent advances in the treatment of adrenocortical carcinomas].
    Ducry J, Berthold D, Pralong F.
    Rev Med Suisse; 2012 Nov 14; 8(362):2181-4, 2186. PubMed ID: 23240320
    [Abstract] [Full Text] [Related]

  • 24. Current and emerging therapies for advanced adrenocortical carcinoma.
    Tacon LJ, Prichard RS, Soon PS, Robinson BG, Clifton-Bligh RJ, Sidhu SB.
    Oncologist; 2011 Nov 14; 16(1):36-48. PubMed ID: 21212436
    [Abstract] [Full Text] [Related]

  • 25. Current update on cytogenetics, taxonomy, diagnosis, and management of adrenocortical carcinoma: what radiologists should know.
    Ganeshan D, Bhosale P, Kundra V.
    AJR Am J Roentgenol; 2012 Dec 14; 199(6):1283-93. PubMed ID: 23169720
    [Abstract] [Full Text] [Related]

  • 26. Adrenocortical cancer: pathophysiology and clinical management.
    Libè R, Fratticci A, Bertherat J.
    Endocr Relat Cancer; 2007 Mar 14; 14(1):13-28. PubMed ID: 17395972
    [Abstract] [Full Text] [Related]

  • 27. Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment.
    Bussey KJ, Demeure MJ.
    Future Oncol; 2009 Jun 14; 5(5):641-55. PubMed ID: 19519204
    [Abstract] [Full Text] [Related]

  • 28. Current and emerging therapies for adrenocortical carcinoma--review.
    Przytulska J, Rogala N, Bednarek-Tupikowska G.
    Adv Clin Exp Med; 2015 Jun 14; 24(2):185-93. PubMed ID: 25931348
    [Abstract] [Full Text] [Related]

  • 29. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
    Kwok GTY, Zhao JT, Glover AR, Gill AJ, Clifton-Bligh R, Robinson BG, Ip JCY, Sidhu SB.
    Oncologist; 2019 Jun 14; 24(6):e241-e250. PubMed ID: 30918109
    [Abstract] [Full Text] [Related]

  • 30. American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach.
    Kiseljak-Vassiliades K, Bancos I, Hamrahian A, Habra M, Vaidya A, Levine AC, Else T.
    Endocr Pract; 2020 Nov 14; 26(11):1366-1383. PubMed ID: 33875173
    [Abstract] [Full Text] [Related]

  • 31. Recent advances in adrenocortical carcinoma in adults.
    Bourdeau I, MacKenzie-Feder J, Lacroix A.
    Curr Opin Endocrinol Diabetes Obes; 2013 Jun 14; 20(3):192-7. PubMed ID: 23549307
    [Abstract] [Full Text] [Related]

  • 32. Pediatric adrenocortical tumor - review and management update.
    Brondani VB, Fragoso MCBV.
    Curr Opin Endocrinol Diabetes Obes; 2020 Jun 14; 27(3):177-186. PubMed ID: 32304390
    [Abstract] [Full Text] [Related]

  • 33. Pediatric adrenocortical carcinoma.
    Ilanchezhian M, Varghese DG, Glod JW, Reilly KM, Widemann BC, Pommier Y, Kaplan RN, Del Rivero J.
    Front Endocrinol (Lausanne); 2022 Jun 14; 13():961650. PubMed ID: 36387865
    [Abstract] [Full Text] [Related]

  • 34. New perspectives for mitotane treatment of adrenocortical carcinoma.
    Puglisi S, Calabrese A, Basile V, Pia A, Reimondo G, Perotti P, Terzolo M.
    Best Pract Res Clin Endocrinol Metab; 2020 May 14; 34(3):101415. PubMed ID: 32179008
    [Abstract] [Full Text] [Related]

  • 35. Adrenocortical carcinoma.
    Soon PS, Sidhu SB.
    Cancer Treat Res; 2010 May 14; 153():187-210. PubMed ID: 19957226
    [No Abstract] [Full Text] [Related]

  • 36. Clinical and molecular prognostic factors in adrenocortical carcinoma.
    Libé R.
    Minerva Endocrinol; 2019 Mar 14; 44(1):58-69. PubMed ID: 30221891
    [Abstract] [Full Text] [Related]

  • 37. Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience.
    Bronswijk MJH, Laenen A, Bechter OE.
    Neoplasma; 2020 Jan 14; 67(1):209-213. PubMed ID: 31777255
    [Abstract] [Full Text] [Related]

  • 38. Advanced Adrenocortical Carcinoma - What to do when First-Line Therapy Fails?
    Megerle F, Kroiss M, Hahner S, Fassnacht M.
    Exp Clin Endocrinol Diabetes; 2019 Feb 14; 127(2-03):109-116. PubMed ID: 30469158
    [Abstract] [Full Text] [Related]

  • 39. Toward a pathway-centered approach for the treatment of adrenocortical carcinoma.
    Bussey KJ, Demeure MJ.
    Curr Opin Oncol; 2011 Jan 14; 23(1):34-44. PubMed ID: 21045685
    [Abstract] [Full Text] [Related]

  • 40. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
    Weigand I, Altieri B, Lacombe AMF, Basile V, Kircher S, Landwehr LS, Schreiner J, Zerbini MCN, Ronchi CL, Megerle F, Berruti A, Canu L, Volante M, Paiva I, Della Casa S, Sbiera S, Fassnacht M, Fragoso MCBV, Terzolo M, Kroiss M.
    J Clin Endocrinol Metab; 2020 Aug 01; 105(8):. PubMed ID: 32449514
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.